The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antihemophilic Factor (Recombinant) Market Research Report 2025
Synopsis
Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.
The global Antihemophilic Factor (Recombinant) market was valued at US$ 2152 million in 2023 and is anticipated to reach US$ 2994.2 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor (Recombinant).
Report Scope
The Antihemophilic Factor (Recombinant) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihemophilic Factor (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor (Recombinant) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
Novo Nordisk
Sanofi
Sobi
Segment by Type
200IU
250IU
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihemophilic Factor (Recombinant) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.
The global Antihemophilic Factor (Recombinant) market was valued at US$ 2152 million in 2023 and is anticipated to reach US$ 2994.2 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The market for recombinant antihemophilic factor has witnessed significant growth in recent years. This can be attributed to several factors, including the increasing prevalence of hemophilia, advancements in recombinant DNA technology, and improved access to healthcare services. Hemophilia is a genetic bleeding disorder that requires lifelong treatment with antihemophilic factors, such as factor VIII or factor IX. Recombinant antihemophilic factor, produced using recombinant DNA technology, offers advantages over plasma-derived products, including enhanced safety, reduced risk of infection transmission, and increased supply stability.
This report aims to provide a comprehensive presentation of the global market for Antihemophilic Factor (Recombinant), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihemophilic Factor (Recombinant).
Report Scope
The Antihemophilic Factor (Recombinant) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antihemophilic Factor (Recombinant) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antihemophilic Factor (Recombinant) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
Novo Nordisk
Sanofi
Sobi
Segment by Type
200IU
250IU
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antihemophilic Factor (Recombinant) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 200IU
1.2.3 250IU
1.3 Market by Application
1.3.1 Global Antihemophilic Factor (Recombinant) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antihemophilic Factor (Recombinant) Market Perspective (2019-2030)
2.2 Antihemophilic Factor (Recombinant) Growth Trends by Region
2.2.1 Global Antihemophilic Factor (Recombinant) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antihemophilic Factor (Recombinant) Historic Market Size by Region (2019-2024)
2.2.3 Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2025-2030)
2.3 Antihemophilic Factor (Recombinant) Market Dynamics
2.3.1 Antihemophilic Factor (Recombinant) Industry Trends
2.3.2 Antihemophilic Factor (Recombinant) Market Drivers
2.3.3 Antihemophilic Factor (Recombinant) Market Challenges
2.3.4 Antihemophilic Factor (Recombinant) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue
3.1.1 Global Top Antihemophilic Factor (Recombinant) Players by Revenue (2019-2024)
3.1.2 Global Antihemophilic Factor (Recombinant) Revenue Market Share by Players (2019-2024)
3.2 Global Antihemophilic Factor (Recombinant) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antihemophilic Factor (Recombinant) Revenue
3.4 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio
3.4.1 Global Antihemophilic Factor (Recombinant) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antihemophilic Factor (Recombinant) Revenue in 2023
3.5 Antihemophilic Factor (Recombinant) Key Players Head office and Area Served
3.6 Key Players Antihemophilic Factor (Recombinant) Product Solution and Service
3.7 Date of Enter into Antihemophilic Factor (Recombinant) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antihemophilic Factor (Recombinant) Breakdown Data by Type
4.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Type (2019-2024)
4.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2025-2030)
5 Antihemophilic Factor (Recombinant) Breakdown Data by Application
5.1 Global Antihemophilic Factor (Recombinant) Historic Market Size by Application (2019-2024)
5.2 Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antihemophilic Factor (Recombinant) Market Size (2019-2030)
6.2 North America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024)
6.4 North America Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antihemophilic Factor (Recombinant) Market Size (2019-2030)
7.2 Europe Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024)
7.4 Europe Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size (2019-2030)
8.2 Asia-Pacific Antihemophilic Factor (Recombinant) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2019-2024)
8.4 Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antihemophilic Factor (Recombinant) Market Size (2019-2030)
9.2 Latin America Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024)
9.4 Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size (2019-2030)
10.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024)
10.4 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Antihemophilic Factor (Recombinant) Introduction
11.1.4 Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.1.5 Takeda Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Antihemophilic Factor (Recombinant) Introduction
11.2.4 Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.2.5 Bayer Recent Development
11.3 CSL
11.3.1 CSL Company Detail
11.3.2 CSL Business Overview
11.3.3 CSL Antihemophilic Factor (Recombinant) Introduction
11.3.4 CSL Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.3.5 CSL Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Antihemophilic Factor (Recombinant) Introduction
11.4.4 Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 Biogen
11.5.1 Biogen Company Detail
11.5.2 Biogen Business Overview
11.5.3 Biogen Antihemophilic Factor (Recombinant) Introduction
11.5.4 Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.5.5 Biogen Recent Development
11.6 Octapharma
11.6.1 Octapharma Company Detail
11.6.2 Octapharma Business Overview
11.6.3 Octapharma Antihemophilic Factor (Recombinant) Introduction
11.6.4 Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.6.5 Octapharma Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Antihemophilic Factor (Recombinant) Introduction
11.7.4 Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Antihemophilic Factor (Recombinant) Introduction
11.8.4 Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Sobi
11.9.1 Sobi Company Detail
11.9.2 Sobi Business Overview
11.9.3 Sobi Antihemophilic Factor (Recombinant) Introduction
11.9.4 Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024)
11.9.5 Sobi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antihemophilic Factor (Recombinant) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of 200IU
Table 3. Key Players of 250IU
Table 4. Global Antihemophilic Factor (Recombinant) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Antihemophilic Factor (Recombinant) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antihemophilic Factor (Recombinant) Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Antihemophilic Factor (Recombinant) Market Share by Region (2019-2024)
Table 8. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Antihemophilic Factor (Recombinant) Market Share by Region (2025-2030)
Table 10. Antihemophilic Factor (Recombinant) Market Trends
Table 11. Antihemophilic Factor (Recombinant) Market Drivers
Table 12. Antihemophilic Factor (Recombinant) Market Challenges
Table 13. Antihemophilic Factor (Recombinant) Market Restraints
Table 14. Global Antihemophilic Factor (Recombinant) Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Antihemophilic Factor (Recombinant) Market Share by Players (2019-2024)
Table 16. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2023)
Table 17. Ranking of Global Top Antihemophilic Factor (Recombinant) Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Antihemophilic Factor (Recombinant) Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Antihemophilic Factor (Recombinant) Product Solution and Service
Table 21. Date of Enter into Antihemophilic Factor (Recombinant) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antihemophilic Factor (Recombinant) Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2019-2024)
Table 25. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Type (2025-2030)
Table 27. Global Antihemophilic Factor (Recombinant) Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2019-2024)
Table 29. Global Antihemophilic Factor (Recombinant) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Application (2025-2030)
Table 31. North America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Country (2025-2030) & (US$ Million)
Table 46. Takeda Company Detail
Table 47. Takeda Business Overview
Table 48. Takeda Antihemophilic Factor (Recombinant) Product
Table 49. Takeda Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 50. Takeda Recent Development
Table 51. Bayer Company Detail
Table 52. Bayer Business Overview
Table 53. Bayer Antihemophilic Factor (Recombinant) Product
Table 54. Bayer Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 55. Bayer Recent Development
Table 56. CSL Company Detail
Table 57. CSL Business Overview
Table 58. CSL Antihemophilic Factor (Recombinant) Product
Table 59. CSL Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 60. CSL Recent Development
Table 61. Pfizer Company Detail
Table 62. Pfizer Business Overview
Table 63. Pfizer Antihemophilic Factor (Recombinant) Product
Table 64. Pfizer Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Biogen Company Detail
Table 67. Biogen Business Overview
Table 68. Biogen Antihemophilic Factor (Recombinant) Product
Table 69. Biogen Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 70. Biogen Recent Development
Table 71. Octapharma Company Detail
Table 72. Octapharma Business Overview
Table 73. Octapharma Antihemophilic Factor (Recombinant) Product
Table 74. Octapharma Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 75. Octapharma Recent Development
Table 76. Novo Nordisk Company Detail
Table 77. Novo Nordisk Business Overview
Table 78. Novo Nordisk Antihemophilic Factor (Recombinant) Product
Table 79. Novo Nordisk Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 80. Novo Nordisk Recent Development
Table 81. Sanofi Company Detail
Table 82. Sanofi Business Overview
Table 83. Sanofi Antihemophilic Factor (Recombinant) Product
Table 84. Sanofi Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 85. Sanofi Recent Development
Table 86. Sobi Company Detail
Table 87. Sobi Business Overview
Table 88. Sobi Antihemophilic Factor (Recombinant) Product
Table 89. Sobi Revenue in Antihemophilic Factor (Recombinant) Business (2019-2024) & (US$ Million)
Table 90. Sobi Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antihemophilic Factor (Recombinant) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Antihemophilic Factor (Recombinant) Market Share by Type: 2023 VS 2030
Figure 3. 200IU Features
Figure 4. 250IU Features
Figure 5. Global Antihemophilic Factor (Recombinant) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Antihemophilic Factor (Recombinant) Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Antihemophilic Factor (Recombinant) Report Years Considered
Figure 10. Global Antihemophilic Factor (Recombinant) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Antihemophilic Factor (Recombinant) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Antihemophilic Factor (Recombinant) Market Share by Region: 2023 VS 2030
Figure 13. Global Antihemophilic Factor (Recombinant) Market Share by Players in 2023
Figure 14. Global Top Antihemophilic Factor (Recombinant) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor (Recombinant) as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2023
Figure 16. North America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Antihemophilic Factor (Recombinant) Market Share by Country (2019-2030)
Figure 18. United States Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Antihemophilic Factor (Recombinant) Market Share by Country (2019-2030)
Figure 22. Germany Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Antihemophilic Factor (Recombinant) Market Share by Region (2019-2030)
Figure 30. China Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Antihemophilic Factor (Recombinant) Market Share by Country (2019-2030)
Figure 38. Mexico Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Antihemophilic Factor (Recombinant) Market Share by Country (2019-2030)
Figure 42. Turkey Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Antihemophilic Factor (Recombinant) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Takeda Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 45. Bayer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 46. CSL Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 47. Pfizer Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 48. Biogen Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 49. Octapharma Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 50. Novo Nordisk Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 51. Sanofi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 52. Sobi Revenue Growth Rate in Antihemophilic Factor (Recombinant) Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
